Cefaclor Dosage
Medically reviewed by Drugs.com. Last updated on Jan 21, 2025.
Applies to the following strengths: 250 mg; 500 mg; 125 mg/5 mL; 250 mg/5 mL; 187 mg/5 mL; 375 mg/5 mL; 375 mg; 125 mg; 187 mg
Usual Adult Dose for:
- Upper Respiratory Tract Infection
- Bronchitis
- Otitis Media
- Pneumonia
- Skin and Structure Infection
- Tonsillitis/Pharyngitis
- Pyelonephritis
- Urinary Tract Infection
Usual Pediatric Dose for:
- Otitis Media
- Tonsillitis/Pharyngitis
- Cystitis
- Pneumonia
- Pyelonephritis
- Urinary Tract Infection
- Skin and Structure Infection
- Bronchitis
- Bacterial Infection
Additional dosage information:
Usual Adult Dose for Upper Respiratory Tract Infection
Immediate release (IR) formulations: 250 to 500 mg orally every 8 hours
Duration of therapy:
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- Group A streptococcal (GAS) infections: At least 10 days
Extended release (ER) tablets: 500 mg orally every 12 hours
- Maximum dose: 1000 mg/day
- Duration of therapy: 7 days
Comments:
- ER tablets given 500 mg orally 2 times a day are only clinically equivalent to IR capsule formulations given 250 mg orally 3 times a day.
- IR formulations: Doses up to 500 mg may be used to treat more severe infections OR infections caused by less susceptible organisms.
- Infections caused by beta-lactamase-negative, ampicillin-resistant (BLNAR) Haemophilus influenzae should be considered resistant to this drug.
Uses:
- Treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis due to H influenzae (only non-beta-lactamase-producing strains), Moraxella catarrhalis (including beta-lactamase-producing strains), or Streptococcus pneumoniae
- Treatment of mild to moderate secondary bacterial infection of acute bronchitis due to H influenzae (only non-beta-lactamase-producing strains), M catarrhalis (including beta-lactamase strains), or S pneumoniae
Usual Adult Dose for Bronchitis
Immediate release (IR) formulations: 250 to 500 mg orally every 8 hours
Duration of therapy:
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- Group A streptococcal (GAS) infections: At least 10 days
Extended release (ER) tablets: 500 mg orally every 12 hours
- Maximum dose: 1000 mg/day
- Duration of therapy: 7 days
Comments:
- ER tablets given 500 mg orally 2 times a day are only clinically equivalent to IR capsule formulations given 250 mg orally 3 times a day.
- IR formulations: Doses up to 500 mg may be used to treat more severe infections OR infections caused by less susceptible organisms.
- Infections caused by beta-lactamase-negative, ampicillin-resistant (BLNAR) Haemophilus influenzae should be considered resistant to this drug.
Uses:
- Treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis due to H influenzae (only non-beta-lactamase-producing strains), Moraxella catarrhalis (including beta-lactamase-producing strains), or Streptococcus pneumoniae
- Treatment of mild to moderate secondary bacterial infection of acute bronchitis due to H influenzae (only non-beta-lactamase-producing strains), M catarrhalis (including beta-lactamase strains), or S pneumoniae
Usual Adult Dose for Otitis Media
IR formulations: 250 to 500 mg orally every 8 hours
Duration of therapy:
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- GAS infections: At least 10 days
Comments:
- Infections caused by BLNAR H influenzae should be considered resistant to this drug.
- IR formulations: Doses up to 500 mg may be used to treat more severe infections OR infections caused by less susceptible organisms.
Use: Treatment of otitis media caused by H influenzae, staphylococci, S pneumoniae, and Streptococcus pyogenes
Usual Adult Dose for Pneumonia
IR formulations: 250 to 500 mg orally every 8 hours
Duration of therapy:
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- GAS infections: At least 10 days
Comments:
- IR formulations: Higher doses should be used to treat more severe infections OR infections caused by less susceptible organisms.
- IR formulations: Doses up to 500 mg may be used to treat more severe infections OR infections caused by less susceptible organisms.
- Infections caused by BLNAR H influenzae should be considered resistant to this drug.
Use: Treatment of lower respiratory tract infections, including pneumonia, caused by H influenzae, S pneumoniae, and S pyogenes
Usual Adult Dose for Skin and Structure Infection
IR formulations: 250 to 500 mg orally every 8 hours
Duration of therapy:
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- GAS infections: At least 10 days
ER tablets: 375 mg orally every 12 hours
- Maximum dose: 750 mg/day
- Duration of therapy: 7 to 10 days
Comments:
- Safety and efficacy in the treatment of skin infections known/potentially caused by S pyogenes with extended-release tablets are unknown.
- IR formulations: Doses up to 500 mg may be used to treat more severe infections OR infections caused by less susceptible organisms.
Uses:
- Treatment of mild to moderate uncomplicated skin and structure infections due to methicillin-susceptible Staphylococcus aureus (MSSA)
- Treatment of skin and structure infections caused by S aureus and S pyogenes
Usual Adult Dose for Tonsillitis/Pharyngitis
IR formulations: 250 to 500 mg orally every 8 hours
Duration of therapy:
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- GAS infections: At least 10 days
ER tablets: 375 mg orally every 12 hours
- Maximum dose: 750 mg/day
- Duration of therapy: 10 days
Comments:
- This drug is generally effective in eradicating nasopharynx and oropharynx infections caused by S pyogenes.
- IM penicillin is the only agent shown to be effective in the prophylaxis of rheumatic fever.
- IR formulations: Doses up to 500 mg may be used to treat more severe infections OR infections caused by less susceptible organisms.
Uses:
- Treatment of mild to moderate pharyngitis and tonsillitis due to S pyogenes
- Treatment of pharyngitis and tonsillitis caused by S pyogenes
Usual Adult Dose for Pyelonephritis
IR formulations: 250 to 500 mg orally every 8 hours
Duration of therapy:
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- GAS infections: At least 10 days
Comments:
- This drug is generally effective in eradicating nasopharynx and oropharynx infections caused by S pyogenes.
- IM penicillin is the only agent shown to be effective in the prophylaxis of rheumatic fever.
- IR formulations: Doses up to 500 mg may be used to treat more severe infections OR infections caused by less susceptible organisms.
Use: Treatment of urinary tract infections, including cystitis and pyelonephritis, caused by coagulase-negative staphylococci, Escherichia coli, Klebsiella species, and Proteus mirabilis
Usual Adult Dose for Urinary Tract Infection
IR formulations: 250 to 500 mg orally every 8 hours
Duration of therapy:
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- GAS infections: At least 10 days
Comments:
- This drug is generally effective in eradicating nasopharynx and oropharynx infections caused by S pyogenes.
- IM penicillin is the only agent shown to be effective in the prophylaxis of rheumatic fever.
- IR formulations: Doses up to 500 mg may be used to treat more severe infections OR infections caused by less susceptible organisms.
Use: Treatment of urinary tract infections, including cystitis and pyelonephritis, caused by coagulase-negative staphylococci, Escherichia coli, Klebsiella species, and Proteus mirabilis
Usual Pediatric Dose for Otitis Media
Children 1 month and older:
IR formulations: 20 mg to 40 mg/kg per day orally, given every 8 to 12 hours
- Maximum dose: 1 gram/day
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- GAS infections: At least 10 days
16 years and older:
ER tablets: 375 mg orally every 12 hours
- Maximum dose: 750 mg/day
- Duration of therapy: 10 days
Comments:
- Efficacy has been established for otitis media and/or pharyngitis/tonsillitis in doses given every 12 hours.
- This drug is generally effective in eradicating oropharynx S pyogenes infections.
- IM penicillin is the only agent shown to be effective in the prophylaxis of rheumatic fever.
- IR formulations: Doses up to 40 mg/kg may be used to treat more severe infections OR infections caused by less susceptible organisms.
- Infections caused by BLNAR H influenzae should be considered resistant to this drug.
Uses:
- Treatment of otitis media caused by H influenzae, staphylococci, S pneumoniae, and S pyogenes
- Treatment of mild to moderate pharyngitis and tonsillitis due to S pyogenes
Usual Pediatric Dose for Tonsillitis/Pharyngitis
Children 1 month and older:
IR formulations: 20 mg to 40 mg/kg per day orally, given every 8 to 12 hours
- Maximum dose: 1 gram/day
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- GAS infections: At least 10 days
16 years and older:
ER tablets: 375 mg orally every 12 hours
- Maximum dose: 750 mg/day
- Duration of therapy: 10 days
Comments:
- Efficacy has been established for otitis media and/or pharyngitis/tonsillitis in doses given every 12 hours.
- This drug is generally effective in eradicating oropharynx S pyogenes infections.
- IM penicillin is the only agent shown to be effective in the prophylaxis of rheumatic fever.
- IR formulations: Doses up to 40 mg/kg may be used to treat more severe infections OR infections caused by less susceptible organisms.
- Infections caused by BLNAR H influenzae should be considered resistant to this drug.
Uses:
- Treatment of otitis media caused by H influenzae, staphylococci, S pneumoniae, and S pyogenes
- Treatment of mild to moderate pharyngitis and tonsillitis due to S pyogenes
Usual Pediatric Dose for Cystitis
IR formulations: 20 mg 40 mg/kg per day orally, given every 8 to 12 hours
- Maximum dose: 1 gram/day
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- GAS infections: At least 10 days
16 years and older:
ER tablets: 375 mg orally every 12 hours
- Maximum dose: 750 mg/day
- Duration of therapy: 7 to 10 days
Comments:
- This drug is generally effective in eradicating nasopharynx and oropharynx infections caused by S pyogenes.
- IM penicillin is the only agent shown to be effective in the prophylaxis of rheumatic fever.
- IR formulations: Doses up to 40 mg/kg may be used to treat more severe infections OR infections caused by less susceptible organisms.
- Infections caused by BLNAR H influenzae should be considered resistant to this drug.
Uses:
- Treatment of lower respiratory tract infections, including pneumonia, caused by H influenzae, S pneumoniae, and S pyogenes
- Treatment of mild to moderate uncomplicated skin and structure infections due to MSSA
- Treatment of skin and structure infections caused by S aureus and S pyogenes
- Treatment of urinary tract infections, including cystitis and pyelonephritis, caused by coagulase-negative staphylococci, E coli, Klebsiella species, and P mirabilis
Usual Pediatric Dose for Pneumonia
IR formulations: 20 mg 40 mg/kg per day orally, given every 8 to 12 hours
- Maximum dose: 1 gram/day
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- GAS infections: At least 10 days
16 years and older:
ER tablets: 375 mg orally every 12 hours
- Maximum dose: 750 mg/day
- Duration of therapy: 7 to 10 days
Comments:
- This drug is generally effective in eradicating nasopharynx and oropharynx infections caused by S pyogenes.
- IM penicillin is the only agent shown to be effective in the prophylaxis of rheumatic fever.
- IR formulations: Doses up to 40 mg/kg may be used to treat more severe infections OR infections caused by less susceptible organisms.
- Infections caused by BLNAR H influenzae should be considered resistant to this drug.
Uses:
- Treatment of lower respiratory tract infections, including pneumonia, caused by H influenzae, S pneumoniae, and S pyogenes
- Treatment of mild to moderate uncomplicated skin and structure infections due to MSSA
- Treatment of skin and structure infections caused by S aureus and S pyogenes
- Treatment of urinary tract infections, including cystitis and pyelonephritis, caused by coagulase-negative staphylococci, E coli, Klebsiella species, and P mirabilis
Usual Pediatric Dose for Pyelonephritis
IR formulations: 20 mg 40 mg/kg per day orally, given every 8 to 12 hours
- Maximum dose: 1 gram/day
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- GAS infections: At least 10 days
16 years and older:
ER tablets: 375 mg orally every 12 hours
- Maximum dose: 750 mg/day
- Duration of therapy: 7 to 10 days
Comments:
- This drug is generally effective in eradicating nasopharynx and oropharynx infections caused by S pyogenes.
- IM penicillin is the only agent shown to be effective in the prophylaxis of rheumatic fever.
- IR formulations: Doses up to 40 mg/kg may be used to treat more severe infections OR infections caused by less susceptible organisms.
- Infections caused by BLNAR H influenzae should be considered resistant to this drug.
Uses:
- Treatment of lower respiratory tract infections, including pneumonia, caused by H influenzae, S pneumoniae, and S pyogenes
- Treatment of mild to moderate uncomplicated skin and structure infections due to MSSA
- Treatment of skin and structure infections caused by S aureus and S pyogenes
- Treatment of urinary tract infections, including cystitis and pyelonephritis, caused by coagulase-negative staphylococci, E coli, Klebsiella species, and P mirabilis
Usual Pediatric Dose for Urinary Tract Infection
IR formulations: 20 mg 40 mg/kg per day orally, given every 8 to 12 hours
- Maximum dose: 1 gram/day
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- GAS infections: At least 10 days
16 years and older:
ER tablets: 375 mg orally every 12 hours
- Maximum dose: 750 mg/day
- Duration of therapy: 7 to 10 days
Comments:
- This drug is generally effective in eradicating nasopharynx and oropharynx infections caused by S pyogenes.
- IM penicillin is the only agent shown to be effective in the prophylaxis of rheumatic fever.
- IR formulations: Doses up to 40 mg/kg may be used to treat more severe infections OR infections caused by less susceptible organisms.
- Infections caused by BLNAR H influenzae should be considered resistant to this drug.
Uses:
- Treatment of lower respiratory tract infections, including pneumonia, caused by H influenzae, S pneumoniae, and S pyogenes
- Treatment of mild to moderate uncomplicated skin and structure infections due to MSSA
- Treatment of skin and structure infections caused by S aureus and S pyogenes
- Treatment of urinary tract infections, including cystitis and pyelonephritis, caused by coagulase-negative staphylococci, E coli, Klebsiella species, and P mirabilis
Usual Pediatric Dose for Skin and Structure Infection
IR formulations: 20 mg 40 mg/kg per day orally, given every 8 to 12 hours
- Maximum dose: 1 gram/day
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- GAS infections: At least 10 days
16 years and older:
ER tablets: 375 mg orally every 12 hours
- Maximum dose: 750 mg/day
- Duration of therapy: 7 to 10 days
Comments:
- This drug is generally effective in eradicating nasopharynx and oropharynx infections caused by S pyogenes.
- IM penicillin is the only agent shown to be effective in the prophylaxis of rheumatic fever.
- IR formulations: Doses up to 40 mg/kg may be used to treat more severe infections OR infections caused by less susceptible organisms.
- Infections caused by BLNAR H influenzae should be considered resistant to this drug.
Uses:
- Treatment of lower respiratory tract infections, including pneumonia, caused by H influenzae, S pneumoniae, and S pyogenes
- Treatment of mild to moderate uncomplicated skin and structure infections due to MSSA
- Treatment of skin and structure infections caused by S aureus and S pyogenes
- Treatment of urinary tract infections, including cystitis and pyelonephritis, caused by coagulase-negative staphylococci, E coli, Klebsiella species, and P mirabilis
Usual Pediatric Dose for Bronchitis
Children 1 month and older:
IR formulations: 20 mg 40 mg/kg per day orally, given every 8 to 12 hours
- Maximum dose: 1 gram/day
- Empirical treatment: At least 48 to 72 hours after the patient becomes asymptomatic OR bacterial eradication evidence is obtained
- Acute bacterial sinusitis: 10 days
- GAS infections: At least 10 days
16 years and older:
ER tablets: 500 mg orally every 12 hours
- Maximum dose: 1000 mg/day
- Duration of therapy: 7 days
- ER tablets given 500 mg orally 2 times a day are only clinically equivalent to immediate-release capsule formulations given 250 mg orally 3 times a day.
- Infections caused by BLNAR H influenzae should be considered resistant to this drug.
Uses:
- Treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis due to H influenzae (only non-beta-lactamase-producing strains), M catarrhalis (including beta-lactamase-producing strains), or S pneumoniae
- Treatment of mild to moderate secondary bacterial infection of acute bronchitis due to H influenzae (only non-beta-lactamase-producing strains), M catarrhalis (including beta-lactamase strains), or S pneumoniae
Usual Pediatric Dose for Bacterial Infection
American Academy of Pediatrics (AAP) Recommendations:
Patients beyond the newborn period:
20 to 40 mg/kg per day, given in divided doses 2 to 3 times a day
- Maximum dose: 1 gram/day
Use: Treatment of bacterial infections
Renal Dose Adjustments
No adjustment recommended.
Liver Dose Adjustments
Data not available
Precautions
CONTRAINDICATIONS:
- Hypersensitivity to the active component, other cephalosporins, or to any of the ingredients
Safety and efficacy of capsules and oral suspensions have not been established in patients younger than 1 month.
Safety and efficacy of ER tablets have not been established in patients younger than 16 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- Many experts recommend that patients should take extended/modified release tablets with food/meals (or at least within 1 hour of eating).
- Capsules and tablets should not be chewed, crushed, or cut.
- Oral suspensions should be shaken prior to administration.
Storage requirements:
- Protect from light.
- The manufacturer product information should be consulted.
Reconstitution/preparation techniques:
- Oral suspension: The manufacturer product information should be consulted.
General:
- Local epidemiological and susceptibility patterns should be used to guide treatment selection in the absence of patient-specific culture and susceptibility information.
Patient advice:
- Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.
- Patients should be directed to take the full course of treatment, even if they feel better.
- Patients should be instructed to report signs/symptoms of Clostridium difficile (e.g., watery/bloody stools, stomach cramps, fever), for up to 2 months after stopping treatment.
More about cefaclor
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Drug images
- Side effects
- During pregnancy
- Drug class: second generation cephalosporins
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Levofloxacin
Levofloxacin is a fluoroquinolone antibiotic used to treat serious bacterial infections and prevent ...
Ceftriaxone
Ceftriaxone systemic is used for bacteremia, bacterial endocarditis prevention, bacterial ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Clindamycin
Clindamycin (Cleocin) is used to treat serious infections caused by bacteria. Includes clindamycin ...
Cephalexin
Cephalexin is a cephalosporin antibiotic used to treat bacterial infections like respiratory, skin ...
Metronidazole
Metronidazole is an antibiotic used to fight bacteria in your body. Learn about side effects ...
Ciprofloxacin
Ciprofloxacin is an antibiotic belong to a group of drugs called fluoroquinolones. Learn about side ...
Doxycycline
Doxycycline is a tetracycline antibiotic used to treat many different bacterial infections such as ...
Azithromycin
Azithromycin is an antibiotic used to treat many different types of infections caused by bacteria ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.